Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

Schizophrenia Research

Volumn 49, Issue 3, 2001, Pages 243-251

  Peet, Malcolm ^a   Brind, Jan ^a   Ramchand, C N ^a   Shah, Sandeep ^b   Vankar, G K ^b  

^a The Price Thomas Thoracic Unit   (United Kingdom)

^b M S UNIVERSITY OF BARODA   (India)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Schizophrenia; Treatment

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; KIRUNAL; NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID; PHOSPHOLIPID DERIVATIVE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FATTY ACID METABOLISM; FEMALE; HUMAN; MALE; PHOSPHOLIPID METABOLISM; PILOT STUDY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; ARACHIDONIC ACIDS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; HUMANS; PILOT PROJECTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0035971559     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(00)00083-9     Document Type: Article

References (63)

1. Abedin L., Lien E.L., Vingrys A.J., Sinclair A.J. The effects of dietary alpha-linolic acid compared with docosahexaenoic acid on brain, retina, liver and heart in the guinea pig. Lipids. 34:1999;475-482.
2. Albers M.A., Meurer H., Märki F., Klotz J. Phosopholipase A2 activity in serum of neuroleptic-naïve psychiatric in patients. Pharmacopsychiatry. 26:1993;94-98.
3. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). fourth ed. 1994;American Psychiatric Association, Washington, DC.
4. Bates E.J., Ferrante A., Harvey D.P., Nandoskar M., Poulos A. Docosahexaenoic acid (22:6, n-3) but not eicosapentaenoic acid (20:5, n-3) can induce neutrophil-mediated injury of cultured endothelial cells: involvement of neutrophil elastase. J. Leukoc. Biol. 54:1993;590-598.
5. Christensen O., Christensen E. Fat consumption and schizophrenia. Acta Psychiatr. Scand. 78:1998;587-591.
6. Adverse effects of the atypical antipsychotics. J. Clin. Psychiatry. 59:(12):1998;17-22.
7. Connor S.L., Connor W.E. Are fish oils beneficial in the prevention and treatment of coronary artery disease? Am. J. Clin. Nutr. 66:(4):1997;1020S-1031S.
8. De Caterina R., Cybulsky M.I., Clinton S.K., Gimbrone M.A. Jr., Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler. Thromb. 14:1994;1829-1836.
9. Delion S., Chalon S., Guilloteau D., Besnard J.C., Durand G. Alpha-linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J. Neurochem. 66:1996;1582-1591.
10. Eaton W.W., Hayward C., Ram R. Schizophrenia and rheumatoid arthritis: a review. Schizophr. Res. 6:1992;181-192.
11. Finnen M.J., Lovell C.R. Purification and characterisation of phospholipase A2 from human epidermis. Biochem. Soc. Trans. 19:1991;91.
12. Fukuzako H., Fukuzako T., Hashiguchi T., Kodama S., Takigawa M., Fujimoto T. Changes in levels of phosphorus metabolites in temporal lobes of drug-naïve schizophrenic patients. Am. J. Psychiatry. 156:1999;1205-1208.
13. Gattaz W.F., Kollisch M., Thuren T., Virtanen J.A., Kinnunen P.K.J. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol. Psychiatry. 22:1987;421-426.
14. Gattaz W.F., Hubner C.K., Nevalainen T.J., Thuren T., Kinnimen P.K.J. Increased serum phospholipase-A2 activity in schizophrenia: a replication study. Biol. Psychiatry. 28:1990;495-501.
15. Gattaz W.F., Schmitt A., Maras A.M. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr. Res. 16:1995;1-6.
16. Gilbert M., Achard F., Dalloz S., Maclouf J., Benistant C., Legarde M. Opposite regulation of prostaglandin H synthase isoforms by eicosapentaenoic and docosahexaenoic acids. Lipids. 34:1999;219.
17. Glen A., Glen E.M., Horrobin D.F., Vaddadi K.S., Spellman M., Morse-Fisher N., Ellis K., Skinner F.S. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr. Res. 12:1994;53-61.
18. Hitzemann R.J., Mark C., Hirschowitz J., Garver D.L. Characteristics of phospholipid methylation in human erythrocyte ghosts: relationship to the psychoses and affective disorders. Biol. Psychiatry. 20:1985;297-307.
19. Horrobin D.F., Manku M.S., Hillman S., Glen A.I. Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry. 30:1991;795-805.
20. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental hypothesis of schizophrenia. Schizophr. Res. 30:1998;193-208.
21. Howe P.R., Clifton P.M., James M.J. Equal antithrombotic and triglyceride-lowering effectiveness of eicosapentaenoic acid-rich and docosahexaenoic acid-rich fish oil supplements. Lipids. 34:1999;S307-S308.
22. Kane J.M., Jeste D.V., Barnes T.E., Casey D.E., Cole J.O., Davis J.M., Gualtieri C.T., Schooler N.R., Spragne R.L., Wettstein R.M. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. 1992;APA, Washington, DC.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
24. Keshaven M.S., Mallinger A.G., Pettegrew J.W., Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res. 49:1993;89-95.
25. Litman B.J., Mitchell D.C. A role for phospholipid polyunsaturation in modulating membrane protein function. Lipids. 31:1996;S193-S197.
26. Loh H.H., Law P.Y. Role of membrane lipids in receptor mechanisms. Ann. Rev. Pharmacol. Toxicol. 20:1980;201-234.
27. Mahadik S.P., Mukherjee S., Correnti E.E., Kelkar H.S., Wakade C.G., Costa R.M., Scheffer R. Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naïve patients at the onset of psychosis. Schizophr. Res. 13:1994;239-247.
28. Manku M.S., Horrobin D.F., Huang S., Morse N. Fatty acids in plasma and red cell membranes. Lipids. 18:1983;906-908.
29. Marteinsdottir I., Horrobin D.F., Stenfors C., Theodorsson E., Mathe A.A. Changes in dietary fatty acids alter phospholipid fatty acid composition in selected regions of rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22:1998;1007-1021.
30. Mellor J., Laugharne J.D.E., Peet M. Omega-3 fatty acid supplementation in schizophrenic patients. Human Psychopharmacol. 11:1996;39-46.
31. Morrow J.D., Awad J.A., Oates J.A., Roberts L.J. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J. Invest. Dermatol. 98:1992;812-815.
32. Noponen M., Sanfilipo M., Samanich K., Ryer H., Ko G., Angrist B., Watkin A., Duncan E., Retrosen J. Elevated PLA2 activity in schizophrenics and other psychiatric disorders. Biol. Psychiatry. 34:1993;641-649.
33. Obata T., Nagakura T., Masaki T., Masaki T., Maekawa K., Yamashita K. Eicosapentaenoic acid inhibits prostaglandin D2 generation by inhibiting cyclo-oxygenase-2 in cultured human mast cells. Clin. Exp. Allergy. 29:1999;1129-1135.
34. Okuda Y., Ezure M., Tsukahara K., Sawada T., Mizutani M., Katori T., Bannai C., Yamashita K. Eicosapentaenoic acid enhances intracellular free calcium in cultured human endothelial cells. Biochem. Med. Metab. Biol. 51:1994;166-168.
35. Pangerl A.M., Steudle A., Jaroni H.W., Rufer R., Gattaz W.F. Increased platelet membrane lysophosphatidylcholine in schizophrenia. Biol. Psychiatry. 30:1991;837-840.
36. Peet M., Laugharne J.D.E., Rangarajan N., Horrobin D.F., Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 29:1995;227-232.
37. Peet M., Laugharne J.D.E., Mellor J. Double-blind trial of fatty acid supplementation in the treatment of schizophrenia. International Congress on Schizophrenia Research, Colorado Springs, CO, April. 1997.
38. Peet M., Glen I., Horrobin D.F. Phospholipid Spectrum Disorder in Schizophrenia. 1999;Marius Press, Carnforth, UK.
39. Pettegrew J.W., Keshevan M.S., Panchalingam K., Strychor S., Kaplan T.B., Tretta M.G., Allen M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naïve schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 48:1991;563-568.
40. Puri B.K., Richardson A.J. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Arch. Gen. Psychiatry. 55:1998;188-189.
41. Ross B.M., Hudson C., Erlich J., Warsh J.J., Kish S.J. Increased phospholipid breakdown in schizophrenia: evidence for the involvement of a calcium-independent phospholipase A2. Arch. Gen. Psychiatry. 54:1997;487-494.
42. Ross B.M. Brain and blood phospholipase activity in psychiatric disorders. Peet M., Glen I., Horrobin D.F. Phospholipid Spectrum Disorder in Psychiatry. 1999;23-29 Marius Press, Carnforth, UK.
43. Rudin D.O. The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol. Psychiatry. 16:1981;837-848.
44. Shah S., Vankar G.K., Telang S.D., Ramchand C.N., Peet M. Eicosapentaenoic acid (EPA) as an adjunct in the treatment of schizophrenia. 9th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, February. 1998.
45. Shah S., Vankar K., Ramchand C.N., Peet M. Lack of niacin skin flush response in unmedicated schizophrenic patients. Schizophr. Res. 2000;. in press.
46. 31P-MR spectroscopy study. Schizophr. Res. 13:1994;209-215.
47. Sumida C., Graber R., Nunez E. Role of fatty acids in signal transduction: modulators and messengers. Prostaglandins Leukot. Essent. Fatty Acids. 48:1993;117-122.
48. Tisdale M.J. Mechanism of lipid mobilisation associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid and inhibitory guanine nucleotide-regulatory protein. Prostaglandins Leukot. Essent. Fatty Acids. 48:1993;105-109.
49. Trzeciak H.I., Kalacinski W., Malecki A., Kokot D. Effect of neuroleptics on phospholipase A2 activity in the brain of rats. Eur. Arch. Psychiatry. Clin. Neurosci. 245:1995;179-182.
50. Tsuang M.T., Stone W.S., Serdman L.J., Faraone S.V., Zimmet S., Wojcik J., Kelleher J.P., Green A.I. Treatment of non-psychotic relatives of patients with schizophrenia: four case studies. Biol. Psychiatry. 45:1999;1412-1418.
51. 1 precursor in chronic neuroleptic-resistant schizophrenic patients. Psychopharmacology. 88:1986;362-367.
52. Vaddadi K.S., Courtney P., Gilleard C.J., Manku M.S., Horrobin D.F. A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res. 27:1989;313-323.
53. Waddington J.L., Scully P.J., O'Callaghan E. The new antipsychotics and their potential for early intervention in schizophrenia. Schizophr. Res. 28:1997;207-222.
54. Ward P.E., Sutherland J., Glen E.M.T., Glen A.I.M. Niacin skin flush in schizophrenia a preliminary report. Schizophr. Res. 29:1998;269-274.
55. Warner R., Laugharne J., Peet M., Brown L., Rogers N. Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: a pilot study. Biol. Psychiatry. 45:1999;1138-1142.
56. Willumsen N., Vaagenes H., Lie O., Rustan A.C., Berge R.K. Eicosapentaenoic acid, but not docosahexaenoic acid, increases mitochondrial fatty acid oxidation and upregulates 2,4-dienoyl-CoA reductase gene expression in rats. Lipids. 31:1996;579-592.
57. Wolkin A., Jordan B., Peselow E., Rubinstein M., Retrosen J. Essential fatty acid supplementation in tardive dyskinesia. Am. J. Psychiatry. 143:1986;912-914.
58. Yao J.K., van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia II: fatty acid composition. Schizophr. Res. 13:1994;217-226.
59. Yao J.K., van Kammen D.P., Welker J.A., Gurklis J. Red blood cell membrane dynamics in schizophrenia III. Correlation of fatty acid abnormalities with clinical measures. Schizophr. Res. 13:1994;227-232.
60. Yao J.K. Red blood cell and platelet fatty acid metabolism in schizophrenia. Peet M., Glen I., Horrobin D.F. Phospholipid Spectrum Disorder in Schizophrenia. 1999;57-74 Marius Press, Carnforth, UK.
61. Yokota K., Tsuruhamim K., Nishimura K., Nagayam T., Jisaka M., Takinami K. Modification of membrane phospholipids with n-6 and n-3 essential fatty acids regulates the gene expression of prostaglandin endoperoxide synthase isoforms upon agonist stimulation. Riemersma R.A., Armstrong R., Kelly R.W., Wilson R. Essential Fatty Acids and Eicosanoids. Invited Papers from the Fourth International Congress. 1998;68-73 AOCS Press, Champaign, IL.
62. Yung A.R., McGorry P.D. Is pre-psychotic intervention realistic in schizophrenia and related disorders? Aust. NZ J. Psychiatry. 31:1997;799-805.
63. Yung A.R., Phillips L.J., McGarry P.D., McFarlane C.A., Francey S., Harrigan S., Patton G.C., Jackson H.J. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br. J. Psychiatry. 172:1998;14-20.